The Uromigos Episode 157: ASCO GU 2022 Sacituzumab and Pembrolizumab in Bladder Cancer

By The Uromigos - Last Updated: September 20, 2022

Dr Petros Grivas describes the results of the phase 2 trial of sacituzumab and pembrolizumab in bladder cancer presented at the 2022 ASCO GU Symposium.

Post Tags:Uromigos-ASCO GU

Related Podcasts

Episode 430: Structured Exercise Improves DFS/OS After Adjuvant Therapy in Colorectal Cancer - Does This Apply to GU Cancers?
Episode 428: ASCO 2025 Recap
Episode 427: Emerging Data in Non-Muscle Invasive Bladder Cancer
Uromigos-Bladder Cancer
Episode 426: ASCO 2025 - AMPLITUDE Phase 3 of PARPi in mHSPC
Uromigos-ASCO
Episode 425: ASCO 2025 - AI-Enabled Selection of Patients for Benefit of ADT + ARPI
Uromigos-ASCO
Advertisement
Advertisement

  • 630 Madison Ave.

    Manalapan, NJ 07726

    • About

    About Us

    Contributors and Partners

    Editorial Policy

    Advertising

    Connect

    eNewsletters

    Calendar

    Contact Us

    Contribute

    Our Network

    MashupMD

    Cancer Nursing Today

    Urban Health Today

    Blood Cancers Today

    DocWire News

    © 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.

    Terms of Use | Privacy Policy |